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Abstract
New technologies have the potential to revolutionize the way we manage health and wellbeing now and in the future. But often
seen as expensive and difficult to implement, the challenge is to identify the best technology to deliver real patient benefit and
support its rapid adoption to help address the funding difficulties faced by all modern healthcare systems. In this paper we
consider the traditional linear model of the technology adoption pathway as it pertains to healthcare, look at common challenges
faced traversing this path and suggest solutions. In so doing, we recognise the limitations of the linear model and describe our
version of a more realistic, non-linear model. Throughout, we will be looking at the key role of the Clinical Engineer to successful
healthcare technology adoption based on our experience of supporting medical device products through to adoption and present
the key lessons we learnt along the way.
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1 Introduction
Modern healthcare is ever more dominated by technologies:
technology has a role in hospitals and in community settings;
in acute episodes and chronic care and indeed technology can
be used to prevent people becoming unwell in the first place
and help us all live longer, healthier lives. New technologies
have the potential to revolutionize the way we manage health
and wellbeing now and in the future. But often seen as expen-
sive and difficult to implement, the challenge is to identify the
best use of technology to ensure it can deliver real patient
benefit and support its adoption to help address the funding
difficulties faced by all modern healthcare systems.
Currently, there is something of a funding crisis in the NHS
in the UK. Estimates vary but the deficit could be as much as
£30bn in the next few years [1]. And it’s not just the NHS or
the UK facing this crisis, healthcare systems all over the globe,
and particularly in the developed world, are struggling to find
sustainable business models. As a population we are getting
older, fatter and more prone to long-term diseases like diabe-
tes, coronary heart disease, and dementia. Our life expectan-
cies have risen sharply over the last couple of decades and our
demands on the healthcare system have risen even more so.
We now expect to be treated for, indeed cured of, conditions
and diseases that a generation ago we were prepared to live
with and indeed die from. And this is of course a really good
news story. As an industry, healthcare has been incredibly
successful, but we are now, in many ways, the victims of
our own success: there are more and more people, expecting
more and more healthcare and the cost of meeting this expec-
tation is increasing much faster than the resources we have at
our disposal.
Since the publication of the UK Government white paper
‘Innovation Health and Wealth’ [2] in 2011, much has been
made about the possible benefits of introducing new technol-
ogy, both in terms of improved patient outcomes and im-
proved productivity. Indeed, it is suggested that much of the
£30bn funding gap predicted in the NHS could be reduced
with the adoption of appropriate technology. But research into
new technologies, development from concepts to finished
medical devices manufactured and distributed to the point of
need, can be challenging and expensive. Navigating this adop-
tion pathway, sometimes referred to as ‘Bench to Bedside’, in
an efficient and timely manner is key to success. In this paper
we explore the technology innovation pathway as it pertains to
healthcare. We consider the traditional linear model of the
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technology innovation, look at common challenges faced tra-
versing this path and suggest solutions. In so doing, we rec-
ognise the limitations of the linear approach and describe our
version of the more realistic, non-linear model. Throughout,
we will be looking at the key role of the Clinical Engineer to
successful healthcare technology adoption based on our expe-
rience of supporting medical device products through to
adoption.
2 The technology adoption pathway –
the linear model
One of the first (conceptual) frameworks developed for under-
standing the relation of science and technology to the econo-
my has been the linear model of innovation. The model pos-
tulates that innovation starts with basic research, is followed
by applied research and development, and ends with produc-
tion and diffusion. The precise source of the model remains
nebulous, having never been documented. Several authors
who have used, improved, or criticized the model in the past
fifty years rarely acknowledged or cited any original source
[3]. The model has been presented in various forms but we
choose to define it as two main phases – Invention and
Implementation - divided into a further 7 stages to describe
as illustrated in Fig. 1.
2.1 Invention phase
The first three stages of the Invention Phase (Conception,
Creation and Confirmation) can be grouped into what is often
referred to as the Design and Development phase. There is
significant discussion in the literature [4] on the design and
development process and we don’t intend to review this here.
Instead, we present our version of the Design and
Development process as we apply it to medical device devel-
opment (see Fig. 2). We make no claim of novelty or unique-
ness but find this presentation simple and easy to apply model
for our development work and reproduce it here to illustrate
this part of the pathway.
The starting point for any new technology is the idea, the
spark, the recognition of the need and the postulation that it
might bemet with some new product or service. In our version
of the pathway we refer to this as the Intent. In the healthcare
setting this typically represents an unmet (or poorly met)
healthcare need and can be generated by a clinician, an engi-
neer or scientist or indeed a patient or member of the public.
One of the great challenges for medical devices innovations is
to bring together this identified need with a potential solution:
the patient struggling with a condition or the clinician with a
diagnosis challenge or a limited treatment options are likely to
be unaware of the scientific research techniques and methods
that the academic teams take for granted. Similarly, the
research scientists and engineers pushing the boundaries of
their respective fields might have no idea of the complex med-
ical and healthcare challenges to which their discoveries might
be applied. All too often we rely on chance meetings or ser-
endipitous encounters to create that spark. An example of this
ad hoc ‘sparking’ from our own experience resulted in the
successful development of a novel neonatal heart rate monitor.
A university-based engineering research team were develop-
ing a pulse sensor to be fitted into the hard hats of miners
working in extreme conditions to act as an early warning alert.
They were presenting their work at a lunchtime seminar when
a neonatal consultant just happened to be in the room for other
reasons and saw the presentation. The medic asked if the tech-
nology could be transferred to the hats worn by premature
babies and the engineering team thought, why not. What
followed was a major success story of collaborative research
and ultimate product release and supply across the NHS; it all
started through this chance meeting [5]. We need to remove
the element of chance from stories like these by creating op-
portunities for researcher and clinician to meet more often,
and the clinical engineer has a key role to play here. Being
embedded within the healthcare provider but also having the
skills, experience and language needed to engage with aca-
demic research teams, clinical engineers have the opportunity,
indeed the duty, to facilitate the meeting of these stakeholders.
Generally, a variety of means are required from formal semi-
nars and conferences to informal gatherings where conversa-
tions often naturally develop into research proposals. We have
a lot of success, for instance, arranging informal dinners where
academics and clinicians meet, enjoy good food and drink
and, with careful and gentle coaching and encouragement
and the right mix of backgrounds and experience, generate
the perfect environment for ‘organised serendipity’.
It is important to capture the outcome of these ‘sparkings’
in some form of a Definition Document. Style and format can
vary but essentially this is the design brief and should include
detail of features that are essential and desirable. The input of
human factors into the design process is becoming increasing-
ly prevalent and is now mandated in the new medical device
regulations [6]. Generally, the Clinical or Biomedical
Engineer is best placed to capture this being able to understand
both the healthcare and the technological context. We refer to
the next stage, which takes this design brief and produces a
prototype, as the Creation stage. This is probably the best
understood part of the pathway, at least by engineers, and is
very much the ‘bench’ end of the Bench to Bedside pathway.
Details of the tasks will of course be dependent on the basic
science and the application but there is always a series of
iterative loops as designs are tested, modified, re-tested, re-
designed and developed. At various points during this stage it
will be necessary to verify that the design delivers perfor-
mance that meets the specification of the design brief. There
might be one or many loops around the verification circuits to
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confirm the prototype does what it set out to do. There will be
restrictions on the designs, not just on what is technically
possible but also what is acceptable within the highly regulat-
ed healthcare environment. It is important during these itera-
tions to keep the Intent in mind; keep referring back to the
original briefing to make sure that the designs are meeting the
identified healthcare need; it is easy at this stage to allow the
engineering design and development to drive the project, al-
low it to drift away from the original intention. Good engi-
neering practice should ensure these design and development
iterations are well managed and documented; key elements of
which include a risk management plan, design file and regu-
latory compliance strategy. Working under an appropriate
Quality Management System (ISO 13485 [7]) whilst always
not essential, is nonetheless the best way to ensure success in
this stage. A successful medical device will ultimately require
the appropriate regulatory approval – for instance CEmarking
in Europe or 510(k) in the USA – for which appropriate tech-
nical documentation will be required [8]. Our experience tells
us that it is never too soon to start collating this information.
What can seem like a bureaucratic overhead in the beginning
pays dividends in the long run as retrospectively collating
evidence for a technical dossier is challenging at best and
impossible at worst. We have seen examples of excellent
innovative technology flounder at the regulatory compliance
hurdle due to poor or non-existent design and technical files.
At some point a final prototype will be produced which has
been designed, developed and tested and can demonstrate, in
the laboratory, that it meets the design brief. This then needs to
be validated through appropriate clinical studies in the
healthcare setting. This validation stage can be difficult and
daunting for non-healthcare professionals. Indeed, even peo-
ple working in the healthcare environment can find it chal-
lenging if unaccustomed to navigating the research and ethic
protocols. Although the process can seem intimidating, it is
generally easy to follow once understood. The secret is to be
prepared and adequately resourced: clinical studies require
time and money; successful cheap shortcuts do not exist.
A robust study design is essential to ensure a successful
outcome [9]. This will help ensure that all necessary practical
requirements are identified early so that adequate funds are
requested. A well-documented study plan will help identify
funding requirements as well as facilitate ethics committee
and local research approvals, healthcare provider permissions,
and any necessary regulatory approvals. Successful clinical
studies often share similar characteristics: they are simple
and tailored to a patient group; designed to address clear ques-
tions of clinical relevance; have the most appropriate choice of
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Fig. 1 Medical Technology Innovation Pathway
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control arm (where required) and have robust blinding of in-
tervention or appropriately blinded outcome assessments (as
necessary). Blinding in medical device trials can be challeng-
ing or impossible so thought must be given to mitigate this.
There is no substitute for experience in this area so it is
necessary to partner with a clinical trials manager or
healthcare statistician when: considering your trial design;
choosing an appropriate outcome; providing justification of
the sample size; advising on appropriate randomisation meth-
odology; drawing up a statistical analysis plan and handling
and structuring collected data. Patient and public involvement
(PPI) is also important to ensure that the question proposed is
important and relevant to the people it directly affects and that
the trial is practical and feasible. There is now a growing
evidence base to support the positive impact that PPI can have
on participation recruitment and retention in clinical studies.
Many funders will require evidence of genuine PPI involve-
ment as a condition of funding [9].
A Med Tech Company or University approaching a
healthcare institution out of the blue with a medical devices
research proposal is going to struggle. So here again is where
the clinical engineers can support the process. While not ex-
pected to be a clinical trials manager or healthcare statistician,
the local clinical engineer should establish good relationships
with these professionals and support the external Med Tech
developer engage effectively. A small spin out Med Tech
company approached us recently looking to gather evidence
to support their CE marking application. This was their first
medical device and they needed support through the whole
validation process. We were able to engage an experienced
clinical trials manager and a medical statistician so that be-
tween us – company, clinical engineers, statistician and trials
manager - we were able to design a study that answered the
appropriate questions for the company’s CE marking applica-
tion, complied with local research and ethics requirements and
made efficient use of hospital and company resources. This
team-based approach worked well for all parties: the company
got the required clinical evidence and the hospital got well
managed, adequately funded, high quality research with good
recruitment.
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The end of the clinical studies generally marks the comple-
tion of the Confirmation stage. There can be a tendency to
allow this to become natural break in the pathway: the clinical
and academic teams have completed their elements, often pa-
pers have been published, technical files completed, proof of
concept confirmed, and prototypes validated in the healthcare
setting. Early investment – usually through publicly funded
research grants or charities - is coming to an end and the route
to market – through scale up, manufacturing, marketing, sales,
distribution and delivery - is often viewed as a separate pro-
cess; as someone else’s responsibility with funding primarily
through commercial backers (venture capitalists, business an-
gels, company reserves or commercial loans). In our experi-
ence this is one of the biggest, and most common, mistakes in
the healthcare technology innovation pathway. For one thing
it is generally naive to believe that a manufacturer who has not
been fully engaged in the development stages can be handed a
prototype and be expected to scale up to a production model,
manufacturer and distribute into a complex healthcare envi-
ronment. Even with the best technical documentation in the
world, it is a challenge for a manufacturer to pick up the baton
at this stage, as it were, from a standing start. Always suppos-
ing, that is, that a suitable manufacturer can be identified who
has the required capabilities and is prepared to take on what
might well be viewed as a risky product.
2.2 The so called ‘Valley of Death’
A further difficulty with this tendency to see the Invention
Phase as separate from the Implementation Phase is that it
has the effect of exacerbating the so called ‘valley of death’:
that point in the development when product is too developed
to continue to attract research funding but not yet mature
enough to generate commercial funding. Much has been writ-
ten about the challenge of technology businesses to bridge this
gap [10, 11] but our experience tells us there are 5 key chal-
lenges for the healthcare innovative product traversing the
gap.
2.2.1 Healthcare environment
A thorough understanding of the healthcare environment, the
patient pathway, alternative treatments and diagnosis and the
needs of the patient group are, of course, essential. The
starting point to gaining this understanding is a health impact
assessment: a relevant literature search and a review of current
practice, including seeking the views of key opinion leaders.
Always ask the patient; clinicians and developers might think
they understand the patients’ needs but there is no substitute
for undertaking formal user needs elicitation utilising the
Human Factors colleagues [6, 12]. It is surprising how often
these exercises throw up important design considerations
overlooked at the initial scoping stage. It is also important to
make sure you take a wide view. A common story we see is
where the product developer has a particular clinical or patient
champion for their technology. The developers get carried
away with the champion’s enthusiasm and produce a fantastic
device which meets their claimed need only to find at that
point, that their champion’s enthusiasm is not shared by the
wider clinical or patient community.
Although most Med Tech developments start with the
healthcare need inmind, this goal is sometimes lost or clouded
before the final product is released. Several iterations of the
design and development loop can see the product drift away
from the original intent. It is therefore important to keep
healthcare environment in mind through the process.
2.2.2 Reimbursement
Whatever the healthcare system – publically funded, insur-
ance-based, or privately funded – somebody somewhere will
need to pay for the medical device if it is to become a success-
fully adopted product. Understanding who that is and what
motivates them to purchase the device is clearly important.
We only have experience of reimbursement in the UK and
mostly through the NHS and hesitate to proffer advice more
widely beyond saying that this is a complex and usually poor-
ly understood area. Therefore, local expertise will be required
across the various healthcare systems.
2.2.3 Regulations
It is true that healthcare is a highly regulated industry and there
are, therefore, significant considerations to be addressed be-
fore a product can be released onto the market and after.
Regulations are often cited as a hurdle in the development
and adoption of new medical device technology, but we en-
courage developers to view themmore as safeguards ensuring
the final products are safe and effective. Successful product
development generally does not see the regulations as added
element to be negotiated, but as an integral part of the initial
design brief. Getting regulatory advice early and designing
compliance from the outset is much easier than trying to ret-
rospectively address regulatory issues with a product nearer
the end of its development phase.
2.2.4 Finance – health economics
Generally, healthcare systems are finite: every pound/euro/
dollar spent on a new medical device is a pound/euro/dollar
that cannot be spent on existing patient care. It is therefore
important to be able to demonstrate that money spent on any
new device will bring at least as much patient benefit as mon-
ey spent elsewhere. In general terms the introduction of a new
medical device into the healthcare system will deliver either
improved, equivalent or reduced patient benefit when
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compared to current care and it will be either cheaper, about
the same or more expensive. There are therefore potentially 9
states such a device can occupy as described in the Table 1.
A device or intervention that delivers reduced patient ben-
efit is unlikely to be adopted into the healthcare system even if
it is cheaper than current care pathways. A device or interven-
tion that brings equivalent patient benefit is only likely to be
adopted into the healthcare system if it is cheaper than current
care pathways. A device or intervention that delivers im-
proved patient benefit is likely to be adopted into the NHS
unless it is more expensive. Successful products therefore tend
to demonstrate improved patient care at the same or equivalent
costs or equivalent patient care at reduced costs and are iden-
tified in Table 1 with a ‘Y’. New devices or interventions
identified in the central diagonal of Table 1 with a ’?’ might
still be adopted but generally would need significant evidence
and support of independent health bodies or royal colleges
to influence buyers and commissioners.
2.2.5 Partners
The above discussions have illustrated the number of stake-
holders required to navigate this far through the innovation
pathway: clinicians, innovators, engineers, designers, regula-
tory experts, health statisticians, ethics experts, clinical trials
managers, human factors experts, health economists, manu-
facturers and, of course, the patients and public. Bringing
these people together and ensuring the appropriate level of
engagement throughout the whole process is perhaps the big-
gest challenge facing the med tech developer. Access to spe-
cific experts at the right time is important but the 3 main
stakeholders that need to be engaged throughout are: the clin-
ical teams (including patients); the developers (usually aca-
demics) and industry. Our experience tells us that successful
product development is most likely where this tri-partnership
is established early and managed throughout.
Collectively, these elements might be defined as Product
Realisation those steps necessary to take across the so called
‘valley of death’, though as we have seen this is not a discrete
process that happens after the clinical studies and before the
product manufacturer but a continuum of activity throughout
the whole innovation pathway.
2.3 Implementation phase
To this point in the linear model of the Innovation Pathway
everything has been about the invention of the device. From
here on, it is about getting that device manufactured, distrib-
uted and deployed to the people who need it; it is about
implementation. See Fig. 3. The first two elements of this
are Good Manufacturing Practice (GMP) and Good
Distribution Practice (GDP) [13].
GoodManufacturing Practice (GMP) is the minimum stan-
dard that a medical device manufacturer must meet in their
production processes. Products must: be of consistent high
quality; be appropriate to their intended use; meet the require-
ments of the marketing authorisation (MA) or product speci-
fication. Good distribution practice (GDP) requires that de-
vices are obtained from the approved supply chain and are
consistently stored, transported and handled under suitable
conditions, as required by the MA or product specification.
TheMed Tech industry have excellent processes in place to
deliver GMP and GDP and, provided they have been engaged
early enough in the pathway and that the design and technical
dossiers are good, these two elements are relatively
straightforward.
The final stage of this linear model is post market surveil-
lance to capture safety and effectiveness reviews which to-
gether allow for future product refinement and improvement.
Rightly the primary purpose of post market stage is to main-
tain patient safety and ensure the benefits identified at the
intent stage are achieved. However, a significant additional
benefit from this work is identifying upgrade possibilities, or
indeed complete redesigns, that would lead to better medical
devices in the future. It is not uncommon, even with the most
rigorously planned clinical studies, to produce unexpected
findings once the device is released and used in the real world.
Feedback from this ‘real-world’ testing can be invaluable. So,
although the final stage of the linear model, this can also be
considered the first stage of a cyclic model (see Fig. 4).
3 The non-linear model
So far we have described the innovation pathway as a number
of discrete stages moving in one direction from initial concep-
tion through to final product release into the healthcare envi-
ronment though we have been clear throughout of the limita-
tions of viewing the innovation in this way. It is a convenient
way to describe innovation development but in reality, it gen-
erally doesn’t work like that. A UK government report [11]
found that less than 1 in 5 successful technology innovations
followed anything close to this route. The idea that publically
funded research ‘invents’ and hands over to commercially
funded industry to ‘implement’ is largely discredited.
Table 1 The Matrix – A
Simple Health
Economics Tool
Patient Benefit
– = +
Cost – ? Y Y
= N ? Y
+ N N ?
Health Technol.
There are a number of papers in the literature describing
alternative models for technology innovation. For example,
Carayannis and Campbell [14] describe the co-evolution and
cross-integration of different innovation drivers (academia,
industry, government and public) in the triple and quadruple
helix models and Jucevoicius and Grumadaite [15] describe
the innovation ecosystem using the approach of complex
theory. However, we prefer a simpler approach. We present
a symbolic representation of this in Fig. 5, accepting it is
figurative only. It is essentially the cyclic model but recognises
that every stage around the cycle is influenced by, and influ-
ences, the other stages. Integration is at the ‘hub’ of this cycle.
It holds the whole process together; facilitates the iterative
feedback; controls risk management; manages relationships;
16
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provides Quality Management overview; ensures regulatory
compliance and keeps the intent, the original vision, alive
throughout the entire innovation path.
4 The role of clinical engineers –
the ‘Integration Hub’
Having been involved in many medical device product devel-
opment projects over the years it became apparent that often
no-one has the time, resources or capabilities to act as the
‘hub’. Generally, the need for this function is overlooked
and as a result neither research funding nor commercial
funding is allocated, resulting in a series of predictable and
avoidable problems occurring throughout the innovation path-
way. Clinical Engineers might not be able to solve all these
problems on their own but can, and we argue are best placed
to, act as the integration hub for the innovation pathway.
Embedded in the healthcare system, we have wide and diverse
experience of the use of medical technology and established
relationship with clinicians and patients. Moreover, with aca-
demic backgrounds and training we are natural bed-fellows of
the university research teams so are ideally placed to facilitate
those initial ‘sparking’ events. Our extensive clinical training
and experience supports our intuitive understanding of the
healthcare environment and our day jobs - of managing
existing and introducing new technology in the clinical setting
- enables us to establish good relationships with the Med Tech
industry. We understand the regulatory framework; are expe-
rienced in project and risk management and often already
work within Quality Management Systems. We might not be
able to meet all the needs of the innovation pathway on our
own - we are not health economists, human factors profes-
sionals, statisticians, ethics or clinical trials managers - but
we are on the ground where these professionals work and
can facilitate collaborative working with them all.
Recognising this missing ‘Integration hub’, and that clini-
cal engineers are the professionals best equipped to create it,
we established a group based within our Clinical Engineering
team offering just this service. We call the group CHEATA
(the Centre for Healthcare Equipment And Technology
Adoption) and have been acting as the ‘integration hub’ for
a number of healthcare technology innovation projects over
the last 4 years; successfully supporting products over part or
all of the innovation pathway [16].
5 Key lessons
After many years of supporting the adoption of healthcare
technology including establishing a dedicated service
(CHEATA) we have learnt a great deal about the innovation
pathway, which we summarise here as 5 key lessons:
5.1 Keep the patient in mind throughout
We’re in this industry to make a difference to patients. Work
with patients and clinicians to establish the healthcare need
early. Clearly define this and keep it central to the innovation.
Don’t allow engineering design, commercial interests,
manufacturing limitations or anything else to obscure this
vision.
5.2 Partnerships
Successful navigation of the innovation pathway for
healthcare technology will require multi-stakeholder engage-
ment. Recognise this and create the right partnerships between
healthcare, academia and industry, as early as possible.
5.3 It’s never too early to utilise HTA
Human factors, health impact assessments, health economics
will all be vital to a successful product development. Don’t
leave these to the final stages but initiate them early as they
will influence the final designs and ensure the best patient
benefit and most economical product.
5.4 Innovation is not linear
It is convenient to talk about the stages of innovations as if it
were a simple linear model. It isn’t – it is a complex ecosystem
which has many loops. Recognise this and create an ‘integra-
tion hub’ to manage the flow though the pathway.
5.5 Clinical engineers should be at the heart of things
We argue that Clinical Engineers are best placed to establish
the ‘integration hub’. Perhaps not traditionally core aspect of
our roles we nonetheless need to develop our teams to support
this function if innovative technology is to be successfully
adopted into our healthcare systems.
6 Conclusion
Our experience over many years of supporting healthcare
technology innovation, and specifically over the last 4 years
through acting as the ‘integration hub’ for many projects,
convinces us that Clinical Engineers can and should be cen-
trally involved in this process. Not only are we best placed to
deliver this function, we have the skills and experience to
drive the innovation forward and the relationships necessary
to deliver the key elements. It is good for us professionally, to
extend our roles and raise our profiles in this way. It is good
for the individual projects and innovations, as we can facilitate
and support smoother and quicker adoptions. It will be
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essential for the future sustainable healthcare systems, as these
new technologies will be vital if we are to meet the increasing
demand for improvements in healthcare whilst at the same
time delivering efficiencies so we can manage within our
resources.
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